Antengene Corp

Antengene Corp FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Antengene Corp (6996.HK) as of Oct 31, 2026 is 74.80 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 119.84 % — a change of -37.58% (lower).

FCF Conversion

74.80 %

YoY

-37.58%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Antengene Corp is 2025 74.80 % . FCF Conversion Rate (FCF/EBITDA) of Antengene Corp was 2024 119.84 % . It decreases by -37.58% lower compared to the previous year.

The Antengene Corp FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
77.83 CNY
Jan 1, 2019
37.51 CNY
Jan 1, 2020
12.25 CNY
Jan 1, 2021
88.64 CNY
Jan 1, 2022
110.65 CNY
Jan 1, 2023
156.04 CNY
Jan 1, 2024
119.84 CNY
Jan 1, 2025
74.80 CNY
The Antengene Corp FCF Conversion history
YEARFCF ConversionYoY
74.80 %-37.58%
119.84 %-23.20%
156.04 %+41.02%
110.65 %+24.84%
88.64 %+623.42%
12.25 %-67.34%
37.51 %-51.80%
77.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Antengene Corp Stock analysis

What does Antengene Corp do? Antengene Corp. Ltd. generates revenue through the development and commercialization of biopharmaceutical products, primarily targeting cancer treatments. The company focuses on ATG-010 (selinexor), which is used for relapsed/refractory multiple myeloma, diffuse large B-cell lymphoma, and non-small cell lung cancer, and ATG-008 (onatasertib), indicated for hepatocellular carcinoma and non-small cell lung cancer. These products are developed for the Asia-Pacific market, where the company conducts its main operations. The firm's revenue streams are derived from the clinical-stage development and eventual commercialization of these therapies, targeting healthcare providers and patients in the region. The company operates as a clinical-stage biopharmaceutical entity, emphasizing discovery, development, manufacturing, and commercialization of innovative cancer treatments. Its primary products, ATG-010 and ATG-008, are designed to address specific oncology indications, with a focus on relapsed or refractory conditions. The Asia-Pacific market serves as the core geographic segment for its business, where it aims to establish a strong presence through its pipeline of biotech products. Revenue is anticipated once these therapies advance through clinical trials and receive regulatory approvals for commercial use. Antengene Corp. Ltd. targets healthcare systems and oncology specialists in the Asia-Pacific region for its biopharmaceutical products. The company’s products are positioned for treatment of complex cancer types, with ATG-010 addressing multiple myeloma and lymphoma, and ATG-008 targeting liver and lung cancers. As a clinical-stage company, its current focus is on advancing these therapies through development stages, with commercialization expected to drive future revenue. The Asia-Pacific market remains central to its business strategy, where it leverages its regional presence to build partnerships and market access. Antengene Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Antengene Corp stock

FCF Conversion Rate (FCF/EBITDA) of Antengene Corp is 74.80 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Antengene Corp changed from 119.84 % to 74.80 %, representing a -37.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Antengene Corp since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Antengene Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Antengene Corp

All Key Metrics — Antengene Corp